Search research articles
Contact Us
Filters
Showing results (61-70 of 83) with videos related to
Page
of 9
Sort By:
Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association
|
January 12, 2021
Asynchronous Telepsychiatry Interviewer Training Recommendations: A Model for Interdisciplinary, Integrated Behavioral Health Care
Michelle Burke Parish, Alvaro Gonzalez, Donald Hilty, et al.
British Journal of Haematology
|
February 16, 2023
Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia
RuiQi Chen, Eshetu G Atenafu, Jack Seki, et al.
Nature Communications
|
June 1, 2017
Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data
Subarna Sinha, Daniel Thomas, Steven Chan, et al.
Leukemia Research
|
October 2, 2024
Outcome of adolescents and young adult acute myeloid leukemia patients compared with middle-aged patients: A single centre retrospective experience
RuiQi Chen, Mohaned AlHumaid, Georgina Daher-Reyes, et al.
Leukemia & Lymphoma
|
June 10, 2017
Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived
Sara Farshchi Zarabi, Steven Chan, Vikas Gupta, et al.
European Journal of Haematology
|
August 8, 2024
Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1-mutated AML
Elliot Smith, Eshetu G Atenafu, Aniket Bankar, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 31, 2025
Identifying Risk Factors and Outcome for CNS Involvement in AML
Jack T Seki, Georgina S Daher-Reyes, Eshetu G Atenafu, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 14, 2025
What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?
Akhil Rajendra, Elliot Smith, Eshetu G Atenafu, et al.
Haematologica
|
January 4, 2020
Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia
Robert Puckrin, Eshetu G Atenafu, Jaime O Claudio, et al.
Blood Cancer Journal
|
August 25, 2025
Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis
Akhil Rajendra, Elliot Smith, Maria Agustina Perusini, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 83) with videos related to
Sort By:
Page
of 9
Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association
|
January 12, 2021
Asynchronous Telepsychiatry Interviewer Training Recommendations: A Model for Interdisciplinary, Integrated Behavioral Health Care
Michelle Burke Parish, Alvaro Gonzalez, Donald Hilty, et al.
British Journal of Haematology
|
February 16, 2023
Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia
RuiQi Chen, Eshetu G Atenafu, Jack Seki, et al.
Nature Communications
|
June 1, 2017
Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data
Subarna Sinha, Daniel Thomas, Steven Chan, et al.
Leukemia Research
|
October 2, 2024
Outcome of adolescents and young adult acute myeloid leukemia patients compared with middle-aged patients: A single centre retrospective experience
RuiQi Chen, Mohaned AlHumaid, Georgina Daher-Reyes, et al.
Leukemia & Lymphoma
|
June 10, 2017
Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived
Sara Farshchi Zarabi, Steven Chan, Vikas Gupta, et al.
European Journal of Haematology
|
August 8, 2024
Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1-mutated AML
Elliot Smith, Eshetu G Atenafu, Aniket Bankar, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 31, 2025
Identifying Risk Factors and Outcome for CNS Involvement in AML
Jack T Seki, Georgina S Daher-Reyes, Eshetu G Atenafu, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 14, 2025
What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?
Akhil Rajendra, Elliot Smith, Eshetu G Atenafu, et al.
Haematologica
|
January 4, 2020
Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia
Robert Puckrin, Eshetu G Atenafu, Jaime O Claudio, et al.
Blood Cancer Journal
|
August 25, 2025
Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis
Akhil Rajendra, Elliot Smith, Maria Agustina Perusini, et al.
Page
of 9